试，被称为 covid-19治疗的随机化评估（恢复） trial, was set up in just ten days and already fifteen patients have been recruited in Exeter. The trial is being run through a strong partnership between the University of Exeter and the Royal Devon & Exeter NHS Foundation Trust. Exeter is one of the 157 trial centres being coordinated nationally by researchers from the University of Oxford. There are currently no specific treatments for COVID-19. It is possible that some existing drugs usually used for other conditions may have some benefits – but they may not. As they are already approved for other uses, the trial is able to start more swiftly than for new drugs which would need rigorous safety testing first. The new trial will provide doctors and the health service with information they need to determine which treatments should be used.
The treatments initially included in the study have been recommended by an expert panel that advises the Chief Medical Officer in England. These are Lopinavir-Ritonavir, normally used to treat HIV, the steroid dexamethasone, which is used in a wide range of conditions to reduce inflammation, and hydroxychloroquine, which is mainly used as an anti-malarial drug and the commonly-used antibiotic azithromycin. The safety and side effects of the drugs are well known. The trial has seen research teams at the RD&E uniting to form a single workforce to ensure that patients have the best possible access to the ground-breaking COVID -9 studies being undertaken. The aim is to promote the most positive outcomes for our patients following infection In the future, the RECOVERY trial may be expanded to assess the impact of other potential treatments as they become available.
Dr Ray Sheridan, Consultant at the Royal Devon & Exeter NHS Foundation Trust and Associate Clinical Professor at the University of Exeter, said: “This trial is an incredibly exciting development in the battle against COVID-19. In Exeter, the strong and long-standing relationship between the University and the RD&E health trust means our clinicians and scientists work incredibly well together. We don’t yet know if the drugs will work, but it’s heartening to be part of promising research on this international crisis. As a frontline clinician, I beg everyone to do their part to buy us time to develop this research. Stay home, wash your hands and when you must go out, observe social distancing measures.”
The trial will be open to adult inpatients at the Royal Devon & Exeter Hospital who have tested positive for COVID-19, and who have not been excluded for medical reasons. All patients will receive the usual standard of care. Patients joining the trial will be allocated at random by computer to receive one of the medicines being studied in addition to standard care, or standard full usual care n. This will enable researchers to see whether any of the possible new treatments are more or less effective than those currently used for patients with COVID-19.
亚光汉考克，状态健康和社会保健部长上周表示; “我们需要更多的专利，志愿者是这些试验的一部分，因为更大的审判，更好的数据和更快，我们可以推出治疗 - 如果，且仅当它被证明工作。但现在，为了保护自己和您的家人免受这种疾病的唯一方法就是留在家里。”
新的审判已经归类为一个紧迫的公共卫生研究性学习。它是一个圆形的项目之一，获得1050万£作为的一部分 £2000万快速反应的研究 由英国研究和创新投资，以及健康和社会保健通过国家卫生研究所的部门。
在56岁的克莱尔·富勒没看见自己作为开发covid-19，尽管她弱及良好管理哮喘的风险特别高 - 但她在人群当中的第一批病人被招募，并在恢复试验的埃克塞特手臂治疗。
A healthy and active global manager for a veterinary company, Claire, from Tiverton in Devon, found herself in isolated treatment at the Royal Devon & Exeter Hospital (RD&E), on oxygen and facing conversations about her options for resuscitation.
Once in hospital, Claire’s COVID-19 test was returned positive, and she was offered the opportunity to sign up to the RECOVERY Trial – A national study led by University of Oxford & run locally In Devon through a partnership between RD&E and University of Exeter. “I was more than happy to sign up,” said Claire. “I know about clinical trials through my work, and I felt it was the least I could do.”
克莱尔被分配了抗疟疾药物羟氯喹，并在她的肺部经历了刺痛，但她说，这是不可能建立这是否是治疗的结果。 “这是很难知道的任何变化是否与药物或病毒，”她说。 “花了一两天，我开始感觉好多了，但我可能永远不会知道这是否会发生呢。”
“The staff at the RD&E were absolutely fantastic, but they’re working under very difficult circumstances. They’re learning with each patient that comes in. They’re having to treat people in isolation conditions – so they wear masks and gloves and only stay long enough to do observations. That’s difficult for everyone involved.